To further confirm that ULK1 deficiency synergizes with p53 activation to induce synthetic lethality in cells and to determine whether this phenomenon extends beyond APG-115, we administered idasanutlin, an alternative MDM2 inhibitor, to two p53 wild-type cancer cell lines. Here, TP53 is linked to cancer.